"Blueprint inks Roche deal with more than $1b in potential payments" by Robert Weisman Globe Staff March 15, 2016
Blueprint Medicines Corp. is teaming up with Roche AG to develop as many as five cancer drugs, a partnership that could bring the five-year-old Cambridge company more than $1 billion.
The deal calls for Roche, a global drug giant based in Switzerland, to make a $45 million upfront cash payment to Blueprint and provide as much as $965 million in option fees and milestone payouts if Roche eventually licenses the drugs and they meet scientific and regulatory goals. Blueprint would also get royalties on Roche’s sales of the drugs.
The collaboration, which the companies unveiled Tuesday, is a vote of confidence in Blueprint’s approach to developing targeted therapies known as kinase inhibitors to treat patients with specific genetic mutations. Blueprint, founded in 2011, went public last April in a $147 million initial public offering that was one of the year’s largest....
I gue$$ reading the Globe is no longer in my genes.
No longer have the heart for it.